Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DY0OR1
|
|||
| Drug Name |
HU6
|
|||
| Synonyms |
HU6
Click to Show/Hide
|
|||
| Drug Type |
Small molecule
|
|||
| Indication | Heart failure with preserved ejection fraction [ICD-11: BD11.0] | Phase 2 | [1] | |
| Non-alcoholic steatohepatitis [ICD-11: DB92.1; ICD-10: K75.8; ICD-9: 571.8] | Phase 2 | [2] | ||
| Company |
Rivus Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C14H16BrN3O
|
|||
| Canonical SMILES |
C1CC(C(C=C1)CNC2=CC(=CC3=C2C=NN3)Br)O
|
|||
| InChI |
InChI=1S/C14H16BrN3O/c15-10-5-12(11-8-17-18-13(11)6-10)16-7-9-3-1-2-4-14(9)19/h1,3,5-6,8-9,14,16,19H,2,4,7H2,(H,17,18)/t9-,14+/m0/s1
|
|||
| InChIKey |
KUCFPVMNWYCZRO-LKFCYVNXSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05284617) Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF). U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04874233) A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2). U.S.National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.